TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immunogenicity of MSB11455 compared to Neulasta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of PBV maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-144h)) of ponesimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of ponesimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma half life (t1/2) of ponesimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Outcome after 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spontaneous breathing trial failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Systolic Cardiac Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological Reactivity in Early Extinction Trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Reactivity in Acquisition Trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Visual Acuity (DVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative GAS Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients developing Nephrogenic Systemic Fibrosis (NSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Change in Amblyopic Eye Visual Acuity at 10 Weeks From Randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between standard FIT results and DRE FIT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positional Stability of Metallic Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gambling Follow-up scale (GFS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of phrenic nerve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Willingness to consider joint replacement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Surgical position accessibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful follow-up with primary care physician
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Percention of Bladder Condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ELGAN admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Choroidal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day hospital readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Serum Intact Fibroblast Growth Factor (FGF-23) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of proviral HIV-1 DNA in total CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opsonophagocytic assay (OPA) titers for PCV13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to therapy assessed with validated score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity after Dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in POSAS total score for Observer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who managed to set the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who managed to perform the test after dynamic tutorial/supervised training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average use of the device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Peak Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of infectious and septic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients on treatment post-dosing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-treatment changes of intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Who Dropped Out or Are Lost to Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Complete Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Binocular HC/HI Visual Acuity at Near (40 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Important Immune-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in T-cell Infiltration in the Tumor After Neoadjuvant Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Achieved a Morphologic Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sensitive teeth (Schiff sensitivity score ≥ 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Left ventricular filling pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E-DME improvement after cataract surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed Complications at the 6-Week Postpartum Visit
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of CTCAE Grade >= 2 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Operative Volume of Chest Tube Drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Percent Time in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in radiographic assessment for periapical inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pulpal sensibility to temperature and electric current
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in root dentin thickness of root canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of target organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Change in Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTRP3 and RBP4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fugl Meyer Assessment Lower Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea Hypopnea Index (AHI) Severity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SpO2 Desaturation Severity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients completing treatment within 1 hour
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Classified as Responders and Non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APGAR score at 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum difference of the mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Device-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Polyp number and size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Water and electrolyte retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in BOLD fMRI Contrasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCSK-9 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Breast Cancer Participants With Sentinel Lymph Nodes Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Premenstrual Depression Symptomatology and Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cold Pain Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities observed
Endpoint domain: Adverse events/effects
Primary endpoint: total learner EBUS-TBNA procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of successful aspirations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival without loss of molecular response major
Endpoint domain: Mortality/survival
Primary endpoint: amount of fat in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of quantifiable cell-free HIV-1 RNA in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of detectable HIV-1 DNA in CSF cell pellets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of respiratory infection-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Deaths during the 4-month influenza season
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants experiencing Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor activity in terms of objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean score on Cohen's Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion experiencing moderate to severe depressive symptoms on the PHQ-8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion experiencing moderate to severe anxiety symptoms on the GAD-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of transmission events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Strength and muscle synergism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of primary Gleason ≥ 3+4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of involuntary movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Characteristics of involuntary movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Amplitude of involuntary movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Worst pain following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects who Experience One or More Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission (CR) after induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in KOOS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Myocardial injury after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Days Needed for Anal Exsufflation After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Electroencephalography (EEG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renal Function Assessed by Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects Achieving Hemostasis at the Named Vessel/Pedicle (Left Side)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Subjects Achieving Hemostasis at the Named Vessel/Pedicle (Right Side)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to initial lung isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: late dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornea Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of the saphenous nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: excessive early deaths
Endpoint domain: Mortality/survival
Primary endpoint: induction failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients showing HBV DNA mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative reintubation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of leaks due to stress incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Subjectively Bothersome Stress Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Count of Participants Needing Retreatment for Stress Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Count of Participants With De Novo or Worsening Urge Incontinence Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adequacy of intraabdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of movement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anatomical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinically significant post-biopsy complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fat Free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Visceral Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality rate (deaths)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Treadmill Walking Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from DR severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological changes from baseline (OCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological changes from baseline (FFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in appendicular muscular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma estrone sulphate inhibitory effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose (MTD) of calcitriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture positivity for Mycobacterium tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes from baseline in PQ/PR interval (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in QRS interval (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in QT corrected for Bazett's formula (QTcB) interval (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in RR interval (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in heart rate (bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration-time profiles of paromomycin sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of siSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of HCV cure
Endpoint domain: Mortality/survival
Primary endpoint: Difference in vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Requirement for the use of extra stomal appliances
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tissue rejection grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective Success Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of peripheral blood mononuclear cell subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychosomatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parental needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Blood serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant autonomic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with urinary disorders identified through accelerometer data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Meal induced fundus relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: perceived parent-adolescent conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: associated health outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients on treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall lung cancer screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmation of diagnosis through prenatal diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute balance compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in perceived provider empathy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceived unmet healthcare needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of grade 3 or 4 allergic reactions
Endpoint domain: Adverse events/effects